Mirati vet Charles Baum named CEO at Terremoto
Plus: Dave Daly at the helm at Exai Bio, and updates from Epitopea and FDA
Charles Baum became CEO at Terremoto Biosciences Inc., which is developing covalent small molecules that bind lysines in target proteins. Baum founded Mirati Therapeutics Inc., whose KRAS inhibitor Krazati adagrasib covalently binds the target via a cystine residue. Baum was CEO at Mirati for nearly a decade, and most recently served as the company’s head of R&D before its acquisition by Bristol Myers Squibb Co. (NYSE:BMY) for $4.8 billion up front. Baum succeeds Peter Thompson who will continue as Terremoto’s chairperson.
Diagnostic company Exai Bio Inc. named Dave Daly CEO. Daly was president and COO of Singular Genomics Systems Inc. (NASDAQ:OMIC). Exai Bio is using AI to develop liquid biopsy tests that measure small, non-coding RNAs secreted by cancer cells into the blood. ...